ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2258

Clinical Associations of Pulmonary Hypertension in RA Patients with and without Interstitial Lung Disease
Abstract Number: 2259

Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
Abstract Number: 2260

Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort
Abstract Number: 2261

Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India
Abstract Number: 2262

Assessment of small airway disease in rheumatoid arthritis
Abstract Number: 2263

Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria
Abstract Number: 2264

Male Sex and Obesity Are Risk Factors for Sarcopenia in RA: Korea National Health and Nutrition Survey 2008–2011
Abstract Number: 2265

Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients
Abstract Number: 2266

Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Abstract Number: 2267

Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Abstract Number: 2268

Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Abstract Number: 2269

Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Abstract Number: 2270

ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs
Abstract Number: 2271

Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Abstract Number: 2272

Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].